Trial Profile
Salirasib for treatment of advanced non-small cell lung cancer: a phase II study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Salirasib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jun 2011 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 08 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2009 Results have been reported in a Concordia Pharmaceuticals media release. Results will also be presented at ASCO.